Stay updated with breaking news from Processing Deficient Progeroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
Global Phase 3 D-LIVR study enrollment completion planned in 2021 Peginterferon Lambda for HDV Global Phase 3 LIMT-2 study initiation planned in 2021 Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies U.S. commercial launch in January 2021 EMA decision expected in 2H21 Lambda for COVID-19 Lancet Respiratory Medicine (Feld et al, 2021) Considering strategic options to advance program Avexitide for Post-Bariatric Hypoglycemia (PBH) Positive Phase 2 PREVENT study published in JCEM (Craig et al, 2021) Corporate Pro-forma cash, cash equivalents and investments...
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021 News provided by Share this article Share this article PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Vir...